Ixazomib citrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ixazomib citrate and what is the scope of freedom to operate?
Ixazomib citrate
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ixazomib citrate has one hundred and eighty-five patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for ixazomib citrate
International Patents: | 185 |
US Patents: | 7 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 37 |
Patent Applications: | 617 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ixazomib citrate |
DailyMed Link: | ixazomib citrate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ixazomib citrate
Generic Entry Date for ixazomib citrate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ixazomib citrate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
AIDS Malignancy Consortium | Phase 2 |
Sun Yat-sen University | Phase 2 |
Takeda | Phase 2 |
Pharmacology for ixazomib citrate
Drug Class | Proteasome Inhibitor |
Mechanism of Action | Proteasome Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ixazomib citrate
Paragraph IV (Patent) Challenges for IXAZOMIB CITRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NINLARO | Capsules | ixazomib citrate | 2.3 mg, 3 mg and 4 mg | 208462 | 1 | 2019-11-20 |
US Patents and Regulatory Information for ixazomib citrate
Expired US Patents for ixazomib citrate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | ⤷ Try for Free | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ixazomib citrate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Taiwan | 201433317 | Boronate ester compounds and pharmaceutical compositions thereof | ⤷ Try for Free |
New Zealand | 624123 | Boronate ester compounds and pharmaceutical compositions thereof | ⤷ Try for Free |
Ukraine | 97536 | ІНГІБІТОРИ ПРОТЕАСОМ[ИНГИБИТОРЫ ПРОТЕАСОМ (PROTEASOME INHIBITORS) | ⤷ Try for Free |
Israel | 203641 | מעכבי פרוטיאזום (Proteasome inhibitors) | ⤷ Try for Free |
Dominican Republic | P2010000384 | COMPUESTOS DE ESTER BORONATO Y COMPOSICIONES FARMACEUTICAS DE LOS MISMOS | ⤷ Try for Free |
Eurasian Patent Organization | 028622 | ИНГИБИТОРЫ ПРОТЕАСОМ (PROTEASOME INHIBITORS) | ⤷ Try for Free |
Cyprus | 1113386 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ixazomib citrate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2178888 | C 2017 012 | Romania | ⤷ Try for Free | PRODUCT NAME: IXAZOMIB SI SARURI SI ESTERI AI ACESTUIA ACCEPTABILE FARMACEUTIC, CA CITRAT DE IXAZOMIB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1094; DATE OF NATIONAL AUTHORISATION: 20161121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1094; DATE OF FIRST AUTHORISATION IN EEA: 20161121 |
2178888 | CR 2017 00014 | Denmark | ⤷ Try for Free | PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE OG ESTERE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123 |
2178888 | PA2017010 | Lithuania | ⤷ Try for Free | PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121 |
2178888 | PA2017010,C2178888 | Lithuania | ⤷ Try for Free | PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA IR ESTERIS, TOKS KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121 |
2178888 | 122017000025 | Germany | ⤷ Try for Free | PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121 |
2178888 | C02178888/01 | Switzerland | ⤷ Try for Free | PRODUCT NAME: IXAZOMIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65959 03.02.2017 |
2178888 | 17/2017 | Austria | ⤷ Try for Free | PRODUCT NAME: IXAZOMIB UND PHARMAZEUTISCH ANNEHMBARE SALZE UND ESTER DAVON, WIE AUCH IXAZOMIB-CITRAT; REGISTRATION NO/DATE: EU/1/16/1094/ 001-003 (MITTEILUNG) 20161123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Ixazomib Citrate
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.